Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening

Ferreira, Luís P.; Gaspar, Vítor M.; Mendes, Luís; Duarte, Iola F.; Mano, João F.

doi:10.1016/j.biomaterials.2021.120983

Cited by 37 publications

(30 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ferreira et al (2021) recapitulated the invasive profile of metastatic BCCs from the development of heterotypic BC spheroids and CAFs in vitro enriched with dECM microfibrillar fragments. In particular, these models exhibited higher expression of key biomarkers and metabolomics, further physio mimetic potential and higher specific resistance to different chemotherapies 133 . As we have shown, recent dECM-based models already highlight their potential as valuable platforms for therapeutic screening, and their ability to reproduce all stages of the tumor 14 .…”

Section: Decellularized Ecm a Promising Bc Biomimetic Model Compared To Conventional Supportsmentioning

confidence: 97%

The biomimetic extracellular matrix: a therapeutic tool for breast cancer research

Tamayo-Angorrilla

Andrés

Jiménez

et al. 2022

Translational Research

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Decellularized Ecm a Promising Bc Biomimetic Model Compared To Conventional Supportsmentioning

confidence: 97%

The biomimetic extracellular matrix: a therapeutic tool for breast cancer research

Tamayo-Angorrilla

Andrés

Jiménez

et al. 2022

Translational Research

View full text Add to dashboard Cite

show abstract

“…Additionally, a recent report showed that breast cancer tumor spheroids could be improved by the addition of decellularized breast tissue microfibers [ 193 ]. This report detailed incorporating tissue-specific ECM from porcine breast tissues during the initial forced aggregation step.…”

Section: Hybrid Tissue Engineering and Use Of Ecmmentioning

confidence: 99%

“…However, by building a middle ground, we can synergize these disparate tissue engineering techniques. A recent account shows that scaffold-free production of 3D in vitro tumor models was improved by incorporation of pelleted decellularized ECM into ultra-low adhesion (ULA) surface prior to cell aggregation [ 193 ]. This technology was also used to recapitulate organotypic features of breast cancers which have not been shown using prior methods.…”

Section: Conclusion and Future Outlookmentioning

confidence: 99%

See 1 more Smart Citation

The ECM: To Scaffold, or Not to Scaffold, That Is the Question

Valdoz

Johnson

Jacobs

et al. 2021

IJMS

View full text Add to dashboard Cite

The extracellular matrix (ECM) has pleiotropic effects, ranging from cell adhesion to cell survival. In tissue engineering, the use of ECM and ECM-like scaffolds has separated the field into two distinct areas—scaffold-based and scaffold-free. Scaffold-free techniques are used in creating reproducible cell aggregates which have massive potential for high-throughput, reproducible drug screening and disease modeling. Though, the lack of ECM prevents certain cells from surviving and proliferating. Thus, tissue engineers use scaffolds to mimic the native ECM and produce organotypic models which show more reliability in disease modeling. However, scaffold-based techniques come at a trade-off of reproducibility and throughput. To bridge the tissue engineering dichotomy, we posit that finding novel ways to incorporate the ECM in scaffold-free cultures can synergize these two disparate techniques.

show abstract

“…Additionally, their complex biochemical composition may induce the synthesis of new ECM by the cells in the scaffold. 10 …”

Section: Current Trends In Bioink Formulationmentioning

confidence: 99%

Trends in Tissue Bioprinting, Cell-Laden Bioink Formulation, and Cell Tracking

et al. 2022

View full text Add to dashboard Cite

Use of three-dimensional bioprinting for the in vitro engineering of tissues has boomed during the past five years. An increasing number of commercial bioinks are available, with suitable mechanical and rheological characteristics and excellent biocompatibility. However, cell-laden bioinks based on a single polymer do not properly mimic the complex extracellular environment needed to tune cell behavior, as required for tissue and organ formation. Processes such as cell aggregation, migration, and tissue patterning should be dynamically monitored, and progress is being made in these areas, most prominently derived from nanoscience. We review recent developments in tissue bioprinting, cellularized bioink formulation, and cell tracking, from both chemistry and cell biology perspectives. We conclude that an interdisciplinary approach including expertise in polymer science, nanoscience, and cell biology/tissue engineering is required to drive further advancements in this field toward clinical application.

show abstract

Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening

Cited by 37 publications

References 111 publications

The biomimetic extracellular matrix: a therapeutic tool for breast cancer research

The biomimetic extracellular matrix: a therapeutic tool for breast cancer research

The ECM: To Scaffold, or Not to Scaffold, That Is the Question

Trends in Tissue Bioprinting, Cell-Laden Bioink Formulation, and Cell Tracking

Contact Info

Product

Resources

About